These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 12829677)
1. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950 [TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699 [TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801 [TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon. Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779 [TBL] [Abstract][Full Text] [Related]
7. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S; Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326 [TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058 [TBL] [Abstract][Full Text] [Related]
12. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578 [TBL] [Abstract][Full Text] [Related]
13. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204 [TBL] [Abstract][Full Text] [Related]
14. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073 [TBL] [Abstract][Full Text] [Related]
15. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Amato RJ; Malya R; Rawat A Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301 [TBL] [Abstract][Full Text] [Related]
17. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820 [TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Amato RJ; Morgan M; Rawat A Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases. Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]